Upfront Briefing
Monday's menu is simple: big pharma opened the wallet. Novartis led with a $1.5B swing for Myricx Bio's ADC payload platform, while AstraZeneca added kidney discovery optionality with a $1.7B CSPC pact structured around just $30M upfront. Elsewhere, biotech kept acting better than broad tech into the break, and the FDA workflow narrative looked steadier than the chaos headlines suggested. Capital allocation is back in the starring role — never a dull hobby.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,483.2 |
0.0% |
9.1% |
| Nasdaq 100 |
29,329.2 |
(1.6%) |
16.4% |
| Russell 2000 |
2,996.1 |
(0.5%) |
19.5% |
| Healthcare (XLV) |
163.7 |
2.6% |
5.3% |
| Biotech (XBI) |
160.5 |
2.5% |
32.0% |
| Nasdaq Biotech (NBI) |
6,764.6 |
3.1% |
18.5% |
| Clinical Trials (BBC) |
52.8 |
2.4% |
40.3% |
|
- Biotech ran against the tape on a rolling ADC M&A bid — Novartis/Myricx the latest payload grab — with the Nasdaq Biotech Index up 3.1% and XBI up 2.5% as generalists rotated into the group.
- The broad tape split on a soft June jobs print (57k added vs. ~113k expected; unemployment 4.2%), which firmed the Fed-hold case; a chip-led selloff dragged the Nasdaq 100 down 1.6% (Tesla −7% on deliveries) and pushed money into healthcare defensives (XLV +2.6%).
- Market data: U.S. cash close Thursday, 2 July 2026.
The Big 3
|
1
|
Novartis to acquire Myricx Bio for up to $1.5 billion
|
- Myricx Bio's NMTi payload platform for antibody-drug conjugates lands at Novartis for up to $1.5 billion, including $1.1 billion upfront cash.
-
Why it matters: Novartis is paying $1.1B cash upfront plus up to $400M in milestones to take full control of Myricx's NMTi payload platform and two lead ADCs against B7-H3 and HER2. The draw is mechanism: NMTi is orthogonal to the TOPO-1 and tubulin payloads that dominate today's ADCs, with preclinical activity in TOPO-1-resistant models — the gap the whole field is chasing. It also resets the price on preclinical ADC platforms: a 2024 Series A ($114M) exiting at up to $1.5B is a marker peers like Tubulis and TORL will note. The catch — both assets are preclinical, so the $400M in milestones sits years and several readouts out.
-
Source:
Novartis
-
More:
Novo Holdings
|
|
2
|
AstraZeneca signs $1.7 billion kidney pact with CSPC
|
- AstraZeneca's kidney drug discovery pact with CSPC covers two kidney disease candidates for up to $1.7 billion, with just $30 million upfront.
-
Why it matters: Classic AstraZeneca-in-China structure: $30M upfront against up to $1.77B ($540M development, $1.2B sales milestones, single-digit royalties), buying an option on two preclinical siRNA candidates built on CSPC's AI-driven, extrahepatic-delivery platform. It's the fourth CSPC pact in under two years — after the 2024 cardiovascular deal, the $5.3B oral-discovery alliance, and January's $18.5B obesity mega-deal — cementing CSPC as AZ's go-to external engine and adding kidney disease as a new target area. The risk is policy, not science: China-sourced BD&L carries live COINS Act overhang, and U.S. lawmakers are actively scrutinising exactly this deal structure.
-
Source:
Fierce Biotech
-
More:
BioSpace;
FirstWord
|
| 3 | United Therapeutics buys Thymmune in deal worth up to $300 million |
-
Thymmune's preclinical regenerative cell therapy assets focused on the thymus are heading to United Therapeutics in a deal worth up to $300 million, including $140 million in cash at closing and up to $160 million in earn-outs.
-
Why it matters: United paid $140M cash plus up to $160M in earn-outs running to 2031 to acquire Thymmune outright, adding an iPSC-derived thymic-cell platform whose lead asset, THY-100, is preclinical in congenital athymia. Against ~$3.5B of cash on hand, the upfront is a rounding error — the point is fit: Thymmune slots into United's organ-manufacturing and transplant-tolerance franchise, the same thesis behind its xenotransplant program, with optional reach into transplant tolerance and autoimmune disease. The catch is duration — everything is preclinical and donor-independent manufacturing is unproven at scale, so value is milestone-gated and long-dated, not a near-term P&L event.
-
Source:
Fierce Biotech
-
More:
BioSpace;
PharmaShots
|
Everything Else that broke
- Ascletis (HKEX: 1672) filed two U.S. obesity INDs — ASC36, a once-monthly amylin receptor agonist, and ASC36_35 FDC, a monthly amylin/GLP-1/GIP co-formulation that outperformed co-administered eloralintide plus tirzepatide by ~51% on relative body-weight loss in a head-to-head DIO rat study. — PR
- ReproNovo dosed the first participant in an EU Phase 2 trial of RPN-002 for embryo implantation. — PR
- BioSpace said FDA decisions stayed mostly steady in H1 2026 despite leadership churn and workforce attrition. — BioSpace
-
On the FDA clock tomorrow (7 July): Vera Therapeutics (VERA) awaits a decision on atacicept for IgA nephropathy, and AstraZeneca/Daiichi Sankyo's Enhertu faces a post-neoadjuvant HER2+ early breast cancer verdict.
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Novartis is buying Myricx Bio for up to $1.5B to add an NMTi payload platform for oncology ADCs (see The Big 3). — PR
- AstraZeneca struck a kidney discovery pact with CSPC worth up to $1.7B, including $30M upfront (see The Big 3). — Fierce Biotech
- United Therapeutics is acquiring Thymmune for $140M to add preclinical thymus-focused regenerative cell therapy assets (see The Big 3). — Fierce Biotech
-
Fosun Wanbang licensed Greater China rights to Junshi's IL-17A psoriasis antibody roconkibart — $32M upfront, up to $166M milestones, double-digit royalties (see Everything Else). — Fierce Biotech
- Sanyou Bio and Baiyunshan Xihe formed a radiopharma and radiodiagnostics collaboration; terms were not disclosed. — PR
- DoH Abu Dhabi and the MIT Koch Institute partnered on AI-driven cancer research; terms were not disclosed. — PR
VC / Private Financings
- No notable VC/private financings since the last edition.
IPOs / Follow-Ons
-
BridgeBio (Nasdaq: BBIO) raised up to $1B in Series A convertible preferred equity — Sixth Street leading with $800M, HealthCare Royalty (a KKR business) funding $133.9M at close — at a 7.00% dividend and a $137.79 initial conversion price (100%+ premium to 30-day VWAP), to fund its Attruby ramp and three near-term launches. — GlobeNewswire
|
